VIRI Virios Therapeutics Inc. Quick Ratio

This chart of the market valuation for Virios Therapeutics (VIRI) demonstrates the 7.35 metric. Virios Therapeutics (VIRI) develops antiviral agents to combat fibromyalgia, targeting individuals with chronic pain. The business relies on global expansion through licensing agreements, which promises high profitability. The project's success is based on clinical test results and the effective management of the R&D budget.

Investors must mitigate the risk of issuer insolvency in the absence of operating income. For Virios Therapeutics (VIRI), whose stability depends on the outcomes of antiviral clinical trials, a liquidity buffer is critical. This quick ratio measures the volume of cash and accounts receivable per unit of liabilities, excluding illiquid inventories. A high ratio confirms the company's ability to fund research without the need for emergency capital raises.